TY - JOUR
T1 - Correction to
T2 - Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)
AU - Amin, Asim
AU - Plimack, Elizabeth R.
AU - Ernstoff, Marc S.
AU - Lewis, Lionel D.
AU - Bauer, Todd M.
AU - McDermott, David F.
AU - Carducci, Michael
AU - Kollmannsberger, Christian
AU - Rini, Brian I.
AU - Heng, Daniel Y.C.
AU - Knox, Jennifer
AU - Voss, Martin H.
AU - Spratlin, Jennifer
AU - Berghorn, Elmer
AU - Yang, Lingfeng
AU - Hammers, Hans J.
N1 - Publisher Copyright:
© 2019 The Author(s).
PY - 2019/3/14
Y1 - 2019/3/14
N2 - Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable." should be replaced with "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable." (3.0% instead of 0.3%). The publisher apologizes for any inconvenience caused by this error.
AB - Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable." should be replaced with "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable." (3.0% instead of 0.3%). The publisher apologizes for any inconvenience caused by this error.
UR - http://www.scopus.com/inward/record.url?scp=85062998201&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000461340300001&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1186/s40425-019-0559-3
DO - 10.1186/s40425-019-0559-3
M3 - Comment/debate
C2 - 30871617
SN - 2051-1426
VL - 7
SP - 73
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 1
M1 - 73
ER -